Trial Profile
A Multicenter, Randomized, Double-Masked, Vehicle-Controlled, Parallel-Group, Phase 2 Study of the Efficacy and Safety of RTA 408 For the Prevention of Corneal Endothelial Cell Loss in Patients Undergoing Cataract Surgery
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 09 Feb 2024
Price :
$35
*
At a glance
- Drugs Omaveloxolone (Primary)
- Indications Ocular inflammation
- Focus Therapeutic Use
- Acronyms GUARD
- Sponsors Reata Pharmaceuticals
- 15 Jul 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 31 Mar 2015 Planned End Date changed from 1 Jun 2015 to 1 May 2015, according to to ClinicalTrials.gov record.
- 17 Feb 2015 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov record.